Dr Naomi Rankin
- Research Associate (Institute of Cardiovascular & Medical Sciences)
- Affiliate (Polyomics Facility)
Naomi works with Professor Naveed Sattar’s laboratory, which specializes in identifying biomarkers for Cardiovascular Disease and Diabetes Mellitus. This group has implemented the Ala-Korpela method for high-throughput serum/plasma metabolomics using proton Nuclear Magnetic Resonance (NMR) spectroscopy (http://www.computationalmedicine.fi). Naomi is also affiliated with Glasgow Polyomics (http://www.polyomics.gla.ac.uk).
Naomi’s research interests focus on the use of NMR for metabolite profiling and advanced lipoprotein profiling of serum and plasma samples. She is particularly interested in the use of these methods in epidemiology/clinical trials, especially with a view towards translation of NMR molecular profiling approaches into the clinic.
Naomi spent 4 years (2008-2012) working as a pre-registration clinical biochemist at the University Hospital of North Staffordshire. This involved biochemical testing of biological fluids using multiple techniques, interpreting results and advising medical colleagues on the significance of these results, the limitations of the tests and potential further investigations indicated.
She was also seconded to the West Midlands Regional Toxicology Laboratory in Birmingham and the Birmingham Children’s Hospital for specialist training. She passed the part 1 exam for the Royal College of Pathologists in 2012.
Naomi graduated from the University of Strathclyde in 2005 with a BSc (Hons) in Biochemistry and Molecular Biology, for which she was awarded the P.J. Heald memorial prize for biochemistry. She completed an MSc in Clinical Biochemistry and a PhD in Glycobiology (“Immunoglobulin G glycosylation as a biomarker for Multiple Sclerosis”) in 2010 from the University of Birmingham and Strathclyde, respectively.
Grants and Awards listed are those received whilst working with the University of Glasgow.
- In-silico quantification of metabolites, lipids and lipoproteins measured by NMR spectroscopy
2016 - 2017
- The use of proton nuclear magnetic resonance to investigate dyslipidaemia and small molecule accumulation in chronic kidney disease (ISSF Catalyst)
2014 - 2015